1. Home
  2. ENTA vs KOPN Comparison

ENTA vs KOPN Comparison

Compare ENTA & KOPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Enanta Pharmaceuticals Inc.

ENTA

Enanta Pharmaceuticals Inc.

HOLD

Current Price

$15.46

Market Cap

486.3M

Sector

Health Care

ML Signal

HOLD

Logo Kopin Corporation

KOPN

Kopin Corporation

HOLD

Current Price

$2.34

Market Cap

424.9M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
ENTA
KOPN
Founded
1995
1984
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Semiconductors
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
486.3M
424.9M
IPO Year
2012
2025

Fundamental Metrics

Financial Performance
Metric
ENTA
KOPN
Price
$15.46
$2.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
3
Target Price
$20.40
$4.25
AVG Volume (30 Days)
173.5K
2.1M
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
29.93
N/A
EPS
N/A
N/A
Revenue
$102,814,000.00
$1,044,337.00
Revenue This Year
$1.94
N/A
Revenue Next Year
N/A
$45.71
P/E Ratio
N/A
N/A
Revenue Growth
16.48
N/A
52 Week Low
$4.09
$0.71
52 Week High
$17.15
$4.16

Technical Indicators

Market Signals
Indicator
ENTA
KOPN
Relative Strength Index (RSI) 66.33 47.84
Support Level $13.39 $2.24
Resistance Level $15.45 $2.58
Average True Range (ATR) 0.76 0.15
MACD 0.13 0.02
Stochastic Oscillator 90.04 71.93

Price Performance

Historical Comparison
ENTA
KOPN

About ENTA Enanta Pharmaceuticals Inc.

Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.

About KOPN Kopin Corporation

Kopin Corp is a provider of high-performance application-specific optical solutions consisting of high-resolution microdisplays and optics, subassemblies, and headsets. It serves soldiers, avionics, armored vehicles training and simulation military applications, and others. Its product portfolio includes Microdisplays, Spatial Light Modulators, Optical Modules, Medical, Training, and Simulation. Geographically, it derives a majority of its revenue from the Americas and also has a presence in Asia-Pacific; Europe, and Other Countries.

Share on Social Networks: